If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Trading Update

7 Nov 2016 07:00

RNS Number : 4343O
Ideagen PLC
07 November 2016
 

7 November 2016

Ideagen plc

("Ideagen" or the "Company")

 

Trading Update

 

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management Software to highly regulated industries, today provides an update on trading for the six months ended 31 October 2016.

 

The Board is pleased to report that trading has remained strong in the first half of the financial year.

 

Revenue and adjusted EBITDA are expected to show a significant increase over the same period last year through a combination of organic growth and the acquisition of Covalent. The Group expects to report organic revenue growth of approximately 16% together with a small contribution from Covalent which was acquired in August 2016. The integration of Covalent is now complete and the Company expects an increased level of contribution in the second half. Consequently, the Company continues to trade in line with market expectations for the full year to 30 April 2017.

 

Cash generation in the period was strong and the Company maintains a robust balance sheet with no debt. The cash balance at the period end was £4.8 million (30 April 2016: £6.3 million), after the payment of £3.8 million for acquisitions and associated costs.

 

David Hornsby, Chief Executive Officer of Ideagen, commented: "This has been a good start to the financial year. Strong trading has been driven by demand across all key vertical markets and continued momentum with our cloud-based Enlighten solution. The market opportunity remains large and long term, and consequently, the Board is optimistic about the Group's continued growth prospects."

 

 

Enquiries:

Ideagen plc

Tel: 01629 699100

David Hornsby, Chief Executive

Graeme Spenceley, Finance Director

finnCap (Nominated Adviser and Broker)

Tel: 020 7220 0500

Stuart Andrews / James Thompson (Corporate Finance)

Stephen Norcross (Corporate Broking)

Alma PR

Tel: 020 8004 4218

Hilary Buchanan

Josh Royston

About Ideagen plc

Ideagen is a UK company quoted on the London Stock Exchange AIM market (Ticker: IDEA.LN). Ideagen is a supplier of Information Management software with operations in the UK, the United States and the Middle East. The Company specialises in eGRC (Enterprise Governance, Risk and Compliance) and Healthcare solutions for organisations operating within highly regulated industries. With an excellent portfolio of software products, Ideagen is able to provide complete content lifecycle solutions that enable organisations to meet their Regulatory and Quality Compliance standards, helping them to reduce costs and improve efficiency.

The Group has a customer base of over 2,200 organisations using the Ideagen suite of products, including many blue chip names such as BAE Systems, Emirates, Shell and the European Central Bank as well as 150 hospitals in the UK and US.

For further information please visit www.ideagen.com

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTVZLFBQFFFFBQ
Date   Source Headline
24th Sep 201810:42 amRNSHolding(s) in Company
17th Sep 20184:42 pmRNSExercise of Options and Total Voting Rights
17th Sep 20184:33 pmRNSHolding(s) in Company
13th Sep 20185:00 pmRNSClosing of conditional Placing to raise £20m
13th Sep 201811:30 amRNSProposed Placing to raise £20 million
5th Sep 20187:00 amRNSAcquisition of InspectionXpert Inc
3rd Sep 20182:36 pmRNSExercise of Options and Total Voting Rights
15th Aug 201812:23 pmRNSHolding(s) in Company
13th Aug 20183:18 pmRNSHolding(s) in Company
13th Aug 20183:05 pmRNSIssue of Shares under Share Incentive Plan and TVR
7th Aug 20181:08 pmRNSHolding(s) in Company
23rd Jul 20183:27 pmRNSIssue of Equity
17th Jul 20187:00 amRNSUnaudited Preliminary Results
18th Jun 20183:38 pmRNSExercise of Options and Total Voting Rights
11th Jun 20185:00 pmRNSIssue of Equity and Total Voting Rights
22nd May 20183:59 pmRNSIssue of Shares under Share Incentive Plan and TVR
15th May 20183:10 pmRNSExercise of Options and Total Voting Rights
9th May 20187:00 amRNSExercise of Options and Total Voting Rights
8th May 20187:00 amRNSPre-Close Trading Update and Board Changes
18th Apr 201810:12 amRNSIssue of Equity
12th Apr 201810:35 amRNSDirector/PDMR Shareholding
11th Apr 20187:00 amRNSDirector/PDMR Shareholding
6th Apr 20187:00 amRNSAcquisition of Medforce Technologies Inc
26th Mar 201812:38 pmRNSHolding(s) in Company
16th Mar 20187:00 amRNSIssue of Shares under Share Incentive Plan and TVR
6th Mar 20183:58 pmRNSExercise of Options and Total Voting Rights
14th Feb 20187:00 amRNSIssue of Equity
23rd Jan 20187:00 amRNSInterim Results
11th Jan 20187:00 amRNSIssue of Equity
13th Dec 201710:18 amRNSDirector Dealing
11th Dec 20172:26 pmRNSIssue of Equity
4th Dec 201712:37 pmRNSExercise of Options and Total Voting Rights
23rd Nov 20177:00 amRNSContract Win
10th Nov 20173:07 pmRNSIssue of Shares under Share Incentive Plan and TVR
7th Nov 20171:26 pmRNSExercise of Options and Total Voting Rights
7th Nov 20177:00 amRNSTrading Update
1st Nov 20175:18 pmRNSPDMR / PCA Dealing
30th Oct 20171:33 pmRNSResult of AGM
25th Oct 20177:00 amRNSExercise of Options and Total Voting Rights
23rd Oct 201710:55 amRNSExercise of Options and Total Voting Rights
16th Oct 20173:30 pmRNSExercise of Options and Total Voting Rights
9th Oct 20174:09 pmRNSIssue of shares under the Share Incentive Plan
6th Oct 20173:13 pmRNSNotice of AGM
27th Sep 20174:28 pmRNSExercise of Options and Total Voting Rights
20th Sep 201710:08 amRNSHolding(s) in Company
4th Sep 20177:00 amRNSBoard Appointment
1st Sep 20173:06 pmRNSIssue of shares under a Share Incentive Plan
11th Aug 20173:00 pmRNSHolding(s) in Company
11th Aug 20178:00 amRNSHolding(s) in Company
10th Aug 20171:36 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.